Senores Pharmaceuticals, Inc. announces the approval and launch of Deferiprone Tablets USP, 500 mg & 1000 mg

Senores Pharmaceuticals, Inc. today announced the launch of Deferiprone Tablets USP, 500 mg & 1000 mg, which is bioequivalent and therapeutically equivalent to Ferriprox Tablets of Chiesi USA, Inc. in the U.S. market. The product will be marketed by Dr. Reddy's Laboratories Inc.

"We are pleased to advance our growth with the launch of a limited-competition product. This aligns with our strategic focus on identifying and entering a niche, under-penetrated generic formulations with an opportunity to serve the unmet needs in healthcare" stated Swapnil Shah, Managing Director, Senores Pharmaceuticals Limited.

Deferiprone Tablets, 500 mg & 1000 mg brand and generic products, had U.S. sales of approximately $70 million MAT for the twelve months ending in October 2025 according to symphony.

Shares of Senores Pharmaceuticals Limited was last trading in BSE at Rs. 764.40 as compared to the previous close of Rs. 765.55. The total number of shares traded during the day was 3693 in over 217 trades.

The stock hit an intraday high of Rs. 771.85 and intraday low of 757.00. The net turnover during the day was Rs. 2821911.00.

Source : Equity Bulls

Keywords

SenoresPharmaceuticals SENORES INE0RB801010 DeferiproneTablets Approval Launch DrReddysLaboratoriesInc